Emerging medical device company experiencing rapid growth
Paoli, PA, Dec. 21, 2015– Dune Medical Devices announced today 100 breast centers have selected MarginProbe to help improve surgical outcomes for lumpectomy patients, marking a significant corporate milestone for the emerging medical device company. To date, there have been over 7,000 MarginProbe lumpectomies performed in 27 states nationwide, and in Israel.
“Since we brought on board a direct sales team in the USA in late 2013, the company has achieved double-digit growth quarter over quarter for eight consecutive quarters, with no signs of slowing down,” said Gil Rosen, chief commercial officer at Dune. In 2015, the company’s average quarter-to-quarter growth rate for installed systems reached 25 percent.
“It’s encouraging to see how quickly the market has embraced such a novel device. The health care industry is aligning itself with the intense focus on quality and improved outcomes, and as a pioneer in improved surgical oncology outcomes, namely fewer repeat breast conserving surgeries and readmissions, we are motivated and well positioned to fill that need,” said Dan Hashimshony, founder and chief executive officer at Dune Medical Devices.
MarginProbe is the first and only FDA-approved technology that offers surgeons a non-invasive assessment that enables real-time detection of cancer at the surface of excised tissue specimens during surgery. By integrating this technology in the operating room, healthcare providers can offer breast cancer patients the greatest chance of achieving clean margins during a lumpectomy procedure.
The MarginProbe System utilizes non-destructive RF Spectroscopy to analyze the outer layer of tissue as either normal or containing clusters of cancer cells. According to pre- and post-market studies, MarginProbe has helped reduce re-excision procedures between 25 and 60 percent and is sensitive enough to detect pure DCIS, a long time challenging target in breast cancer treatment.
About Dune Medical Devices
Dune Medical Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real-time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications.